

## Datasheet: PIP045

|                      |                      |
|----------------------|----------------------|
| <b>Description:</b>  | NATIVE RUBELLA VIRUS |
| <b>Name:</b>         | RUBELLA VIRUS        |
| <b>Format:</b>       | Inactivated Pathogen |
| <b>Product Type:</b> | Antigen              |
| <b>Quantity:</b>     | 1 mg                 |

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

|       | Yes | No | Not Determined | Suggested Dilution |
|-------|-----|----|----------------|--------------------|
| ELISA | ▪   |    |                |                    |

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

|                                       |  |
|---------------------------------------|--|
| <b>Target Species</b>                 | Viral  |
| <b>Product Form</b>                   | Inactivated Rubella virus - liquid   |
| <b>Preparation</b>                    | Rubella virus, HPV-77 strain, cultured in Vero cells, an established cell line from African Green Monkey kidney. Infected cells release virus particles into the culture supernatant. The supernatant is harvested, clarified and concentrated. The virus suspension is purified by two cycles of sucrose gradient purification. The antigen preparation is inactivated by exposure to UV light. This method leads to maximum loss of infectivity with a minimum loss of antigenicity. |
| <b>Buffer Solution</b>                | NTE buffer (Sodium chloride, Tris and EDTA)  |
| <b>Preservative Stabilisers</b>       | None present   |
| <b>Approx. Protein Concentrations</b> | Total protein concentration 0.51 mg/ml   |
| <b>Product Information</b>            | <b>Native Rubella virus preparation</b> contains more than 90% virus specific protein. The predominant form of the antigen is whole virions suspended in NTE buffer with 20%   |

sucrose. Some residual non-viral protein from the host tissue is present. The preparation does not contain detergent..

Rubella virus is an enveloped, single-stranded RNA virus of the *Togaviridae* family. Infection with the virus leads to rubella, commonly known as German measles, a common childhood illness. The primary symptom is a rash on the face, trunk and limbs which normally fades after about three days. Fever, swollen glands, joint pains, headaches and conjunctivitis may also be present. Symptoms are usually mild and the virus is rapidly eliminated from the body. Infection of a pregnant woman is potentially serious since the child may be born with congenital rubella syndrome, characterised by cardiac, cerebral, ocular and auditory defects.

For a Rubella virus preparation of lower purity, please see [PIP044](#).

---

|                                      |  |
|--------------------------------------|--|
| <b>Activity</b>                      | This product has been rendered inactive by standard procedures. However this material should still be handled as infectious and should be disposed of appropriately.                                     |
| <b>Instructions For Use</b>          | PIP045 should be sonicated immediately before use to ensure the preparation is uniform. The product may be used in a variety of immunoassay formats.   |
| <b>Storage</b>                       | Store at -70°C.<br>Storage in frost-free freezers is not recommended.<br>This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the protein.                  |
| <b>Guarantee</b>                     | 18 months from date of despatch  |
| <b>Health And Safety Information</b> | Material Safety Datasheet documentation #10503 available at:<br>10503: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10503.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10503.pdf</a> |
| <b>Regulatory</b>                    | For research purposes only   |

---

**North & South America** Tel: +1 800 265 7376  
Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700  
Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21  
Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

From March 15, 2021, we will no longer supply printed datasheets with our products.  
Look out for updates on how to access your digital version at [bio-rad-antibodies.com](http://bio-rad-antibodies.com)

'M353498:190429'

**Printed on 09 Feb 2021**